Dr. Mateos on the Significance of the CANOVA Trial in R/R t(11;14) Myeloma

Video

María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.

María-Victoria Mateos, MD, PhD, an associate professor of medicine and director of the Myeloma unit at the University of Salamanca in Spain, discusses the significance of the ongoing phase 3 CANOVA trial,which is examining venetoclax (Venclexta) in patients with relapsed/refractory t(11;14) multiple myeloma.

In the multicenter, open-label CANOVA study, patients with relapsed/refractory, t(11;14)–positive multiple myeloma were randomized to receive either venetoclax plus dexamethasone or pomalidomide (Pomalyst) plus dexamethasone. t(11;14) in multiple myeloma is a cytogenetic abnormality, usually present in approximately 15% to 20% of patients, says Mateos. 

Venetoclax is the first targeted therapy being used to treat patients with multiple myeloma, explains Mateos. This is important because if all patients with t(11;14) in this study are shown to be candidates to receive venetoclax, then all patients with the translocation can receive this drug, concludes Mateos.

Related Videos
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Don S. Dizon, MD